STUDY OF NEUROVIRULENT PROPERTIES OF VACCINE AGAINST CULTURAL LIVE RUBELLA
Педиатрическая фармакология, 2010 Experts at FSUE R&D Centre Microgen of the RF’s Healthcare Ministry have developed a national drug designed to prevent rubella — Cultural live vaccine against rubella on the basis of vaccinal strain RA 27/3.
A.N. Mironov +5 more
doaj +2 more sources
Prevention of infectious diseases in athletes. [PDF]
, 2007 The sports medicine physician may face challenging issues regarding infectious diseases when dealing with teams or highly competitive athletes who have difficulties taking time off to recover.
d'Hemecourt, Pierre, Luke, Anthony
core
Rubella serosurveys at three Aravind Eye Hospitals in Tamil Nadu, India
Bulletin of the World Health Organization, 2004 OBJECTIVE: To determine the susceptibility of female eye hospital staff to rubella infection and the potential risk for hospital-based rubella outbreaks. METHODS: A prospective cohort study on the seroprevalence of rubella IgG antibodies was conducted at
Vijayalakshmi Perumalsamy +7 more
doaj
Safety of measles, mumps, and rubella vaccine in adolescents and adults in the vaccine safety Datalink. [PDF]
Vaccine X, 2023 Hanson KE +11 more
europepmc +1 more source
Measles, mumps and rubella vaccine 12 months after hematopoietic stem cell transplantation. [PDF]
Rev Inst Med Trop Sao Paulo, 2023 Randi BA +6 more
europepmc +1 more source
Microtitration of Rubella Virus in Monovalent Vaccinal Products
Iranian Journal of Public Health, 2011 Background: Potency test for control of rubella vaccine is a significant factor to qualify production line and vaccination program. For this reason, WHO recommends to use the microtitration method by both vaccine companies and control laboratories ...
F Esna-Ashari +9 more
doaj
Can We Justify Intralesional Immunotherapy with Measles-mumps-rubella Vaccine for Recalcitrant Facial Warts? [PDF]
Oman Med J, 2022 Al-Mendalawi MD.
europepmc +1 more source
Efficacy of Intralesional Measles Mumps Rubella Vaccine in the Treatment of Verruca Vulgaris: An Interventional Study. [PDF]
Cureus, 2023 Surani AS, Un R, Marfatia Y.
europepmc +1 more source
A phase II/III randomised, comparative study evaluating the safety and immunogenicity of Biological E's live, attenuated Measles-Rubella vaccine in 9-12 month old healthy infants. [PDF]
Contemp Clin Trials Commun, 2023 Thuluva S +7 more
europepmc +1 more source